New #OpenAccess study suggest that neoadjuvant platinum-based ICI-chemo. for those with early-stage #NSCLC is associated with improvements in 2-year EFS and pCR 🫁

See the full study in JAMA Network Open by Giuseppe Banna, Mona Hassan, Alfredo Addeo MD & colleagues ⬇️

jamanetwork.com/journals/jaman…

See the updated ASCO living guideline in Journal of Clinical Oncology which provides expert insights into common clinical scenarios encountered when caring for those with advanced #NSCLC 🫁

#OpenAccess article by Dwight Owen, Narjust Florez, MD, FASCO, Erin Schenk, MD, PhD, Jyoti D Patel and colleagues ⬇️

1/ 🧵 Pleased to share our latest manuscript #lungcancer . Our, Giuseppe Banna Alessio Signori & al, review and meta-analysis has explored the effectiveness of combining immune checkpoint inhibitors (ICIs) with chemotherapy for early-stage non-small cell lung cancer.
We pooled results

Meta-analysis of neoadjuv chemoimmunotherapy in #NSCLC :
1. 3 cycles suffice based on pCR, with adjuvant immunotherapy not enhancing EFS.
2. Kudos to JAMA Network Open team, esp. Sara, for elevating paper quality & reviewers' feedback.
3. Special shoutout to the amazing team!

New research from Maxime Borgeaud, Timothée Olivier, MD, Alfredo Addeo MD & colleagues finds that 2nd generation #TKI afatinib demonstrates efficacy for G719X, S768I, E709X and L747X mutations, as well as for compound uncommon mutations in #NSCLC 🫁

See the open access article in JTO & JTO CRR ⬇️

Don't miss the new ESMO - Eur. Oncology living guideline on non-oncogene-addicted metastatic #NSCLC by Lizza Hendriks, Martin Reck & colleagues!

See the up-to-date treatment algorithms and guidelines ⬇️

Don't miss the ASCO Educational Book on novel treatment strategies for those with #EGFR -mutant #NSCLC across all stages 🫁

#OpenAccess book by Stephanie Saw, Xiuning Le MD PhD, Lizza Hendriks and Jordi Remon ⬇️

See the updated ASCO living guideline in Journal of Clinical Oncology which provides expert insights into common clinical scenarios encountered when caring for those with advanced #NSCLC 🫁

#OpenAccess article by Dwight Owen, Narjust Florez, MD, FASCO, Erin Schenk, MD, PhD, Jyoti D Patel and colleagues ⬇️

How can we advance the standard of treatment for those with oncogene-driven #LungCancer ? 🫁

An interesting question by Zosia Piotrowska for Lizza Hendriks and all those at the #ILCS23 conference.

Hear their thoughts below and catch the full discussion online ⬇️

Is there a role for metronomic #immunotherapy for those with #lungcancer , especially in low- and middle-income countries ( #LMICs )?

Listen to Solange Peters and charocampelo on this very question, and more from the latest #ILCS23 ⬇️

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Don't miss the ASCO Educational Book on novel treatment strategies for those with #EGFR -mutant #NSCLC across all stages 🫁

#OpenAccess book by Stephanie Saw, Xiuning Le MD PhD, Lizza Hendriks and Jordi Remon ⬇️

Results from KEYNOTE-B99 from Dr. Delvys Rodriguez Abreu at #AACR24 : phase II study in #SCLC of 1L pembrolizumab + EP + either MK-4830 (anti-ILT4), MK-5890 (boserolimab, CD27 agonist), or lenvatinib. RR 65-74% and mPFS 5.5-7.2 months.

Lung cancer was the most frequently diagnosed cancer and the leading cause of cancer death in 2022, according to the new global cancer statistics from American Cancer Society & IARC 🫁

See the full #openaccess article in CA: A Cancer Journal for Clinicians by Freddie Bray, Ahmedin Jemal & colleagues ⬇️

How to treat advanced NSCLC with driver mutations . First line and second line . Nice tables for quick reference during clinical practice. ASCO Journal of Clinical Oncology. Note that anti her2 drugs and anti KRas drugs are for second line only .

#lungcancer is the #1 cause of #cancer related deaths worldwide 🌏.
➡️ But did you know that #Lungcancer in Never Smokers (LCINS) is the 5th most common cause of #cancer related deaths 🌏?
Fantastic talk by Elaine Shum from NYU Langone Health today at #AACR24 . AACR OncoAlert

Lung cancer was the most frequently diagnosed cancer and the leading cause of cancer death in 2022, according to the new global cancer statistics from American Cancer Society & IARC 🫁

See the full #openaccess article in CA: A Cancer Journal for Clinicians by Freddie Bray, Ahmedin Jemal & colleagues ⬇️

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24 , out in Cancer Discovery today rb.gy/q484j9 Tweetorial👇

Atezolizumab + cabozantinib after disease progression following anti–PD-L1/PD-1 immunotherapy & platinum-containing chemo for metastatic #NSCLC did not improve OS compared with docetaxel, finds CONTACT-01 study.

Article in Journal of Clinical Oncology by Joel W. Neal, MD, PhD, Tom Newsom-Davis & colleagues ⬇️

A must read paper in CA: A Cancer Journal for Clinicians and American Cancer Society on the GLOBAL burden of cancer: insights into trends, interventions and priorities worldwide!

OncoAlert Karen Knudsen, MBA PhD

acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…